Date post: | 12-Oct-2015 |
Category: |
Documents |
Upload: | sreekanthsharma |
View: | 13 times |
Download: | 0 times |
of 31
III. Critical Stability Operationsd St bilit P t land Stability Protocols
Critical Stability Systems
Regulations ProceduresRegulations(I)
Procedures(II)
Stability Systems
Operations(III)
Investigations(IV)
Copyright USP. All rights reserved.
Discussion Topics
3. Best Practices on Stability Operations
` Establish compliant stability protocols` Establish compliant stability protocols
` Define Stability Day-to-Day Operations
` Discuss best practices on these operations
` Discuss key factors of environmental chambers
Copyright USP. All rights reserved.
Documentation Practices: Stability Protocol
1. Contents of a Stability Protocol2. Storage conditions3. Selection of batches4. Testing frequency5. Specifications / tests6. Reduced design (Bracketing and Matrixing)7. General considerations
Copyright USP. All rights reserved.
Typical Global Stability Protocol
TEMP TZ 1 2 3 6 9 12 18 24 36HUMIDITY TZ Mo Mo3
Mo6
mo Mo Mo8
Mo mo36Mo
25 C25 C60%RH X X X X X X X X
30 C65%RH X X X X (X) (X) (X)
(30 C75%RH) X X X X X X X X
40 C75%RH X (X) X X (X) (X)75%RH ( ) ( ) ( )
50 C X
5 C H O L D
Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best Practices, K. Huynh-Ba (ed.), Springer, November 2008, Chapter 2.
Special Storage Conditions
` Photostability: two types of studies: Forced degradation study to generate potential g y g p
degradation products
Confirmatory study to confirm product and package fperformance
` For liquids in semi-permeable package Long term: 25C/40%RH
Intermediate: 30C/65%RH
Accelerated: 40C/
Special Storage Conditions
` To support adverse shipping and unusual storage of samples (liquid)
Freeze Thaw Cycling (-10C to -20C four days, 25C or 25C/60%RH for three days)
Th l C li (40C f d ilib t t 25C Thermal Cycling (40C four days, equilibrate to 25C and then 5C for three days)
Copyright USP. All rights reserved.
Contents of a Stability Protocol
Stability studies are initiated based on approved stability protocols:
Identity of product: name, strength Description of dosage form or formulation Purpose of study Manufacturing site, packaging and testing sites. Details of packages (container/closure) Instructions for receipt and allocation of material Shipping of material (if needed)
Copyright USP. All rights reserved.
Contents of a Stability Protocol
Storage conditions, time-points, configuration, orientation (if applicable)
Testing information: tests and specifications
Each study has unique, identifying number for LIMS orEach study has unique, identifying number for LIMS or specific tracking system.
Global conditions for products which are expected to beGlobal conditions for products which are expected to be sold and used worldwide.
Change of protocols: Deviations vs Admendmentsg p
Copyright USP. All rights reserved.
Specification / Tests
The testing covers physical, chemical and microbiological attributes, preservative content (e.g.
ti id t ti i bi l ti ) dantioxidant, antimicrobial preservative), and functionality tests (e.g. for a dose delivery system).
What tests at each time points? Which labs? What tests at each time points? Which labs?
Shelf life acceptance criteria derived from available stability information? Alert limits?y
Differences between the shelf life and release specs are justified based on the stability evaluation and the changes observed on storage.
Copyright USP. All rights reserved.
Stability Practices
` Management of deviations and protocol amendments
` Chamber Monitoring System` Chamber Monitoring System
` Study Activation Procedure
` Sample Pulling and Testing Procedure
` Sample Custodian Procedure
` Sample Destruction Procedure
` Sample Shipping Procedure` Sample Shipping Procedure
` Study Cancellation
Copyright USP. All rights reserved.
` Chamber Inventory Program
Critical Stability Dates
Expiration DateStudy Start DatePackaging
Date p(Study End Date)
ReleaseDate
Stability Pull DatesManufacturing
Date
yDate
Batch Manufactured
R l T ti
Stability Scheduled Testing
Drug Product Expiry
TZ* Testing
Release Testing
S
12
Stability Testing in Pharmaceutical Development Handbook: Regulations, Methodologies and Best Practices, K.Huynh-Ba, ed., Springer 2008.
Environmental Chambers
` Two basic types: Reach-In and Walk-In
Reach-in chambers can be a self-contained units with good profile control, but have limited space.
Walk-in chambers have more storage space but are more difficult to control and validate
All chamber units must have temperature and humidity control over a defined range with suitable tolerances tocontrol over a defined range with suitable tolerances to meet ICH specifications. Must have continuous monitoring of parameters to allow documentation of
Copyright USP. All rights reserved.
chamber integrity at all times.
Environmental Chambers
Walk-inChambers
Courtesy of Luwa Americaswww.luwaamericas.com
14
Key Factors of Stability Chambers
` Chamber should be calibrated to appropriate technical specs.
` Chamber should be validated with profiling matrix.` Temperature and humidity should be recorded
ti lcontinuously.
` SOPs for operation of chamber should be prepared and controlledcontrolled.
` Units should have logbooks for maintenance and repairs.p
Copyright USP. All rights reserved.
Key Factors of Stability Chambers
` Units should have secured access to prevent tampering.` If electronic information is collected, the system should
be compliant with 21CFR11 requirements.
` Alarm and backup systems should be in place to detect f il d t t ti f hipower failures and prevent station from crashing.
` Procedures should be in place for man-made or natural disastersdisasters.
Copyright USP. All rights reserved.
B k ti d M t i iBracketing and Matrixing
What is Bracketing?
` The design of a stability schedule such that at any time point only the samples on the extremes of certain d i f t ( t th k i ) t t ddesign factors (e.g., strength, package size) are tested at all time points as in a full design. The design assumes that the stability of the intermediate levels is represented by the extremes tested
Copyright USP. All rights reserved.
What is Bracketing?
` ...Where a range of strengths is to be tested, bracketing designs may be particularly applicable if the t th id ti l l l l t d istrengths are identical or very closely related in
composition (e.g., for a tablet range made with different compression weights of a similar basic granulation, or a capsule range made by filling different plug fill weights of the same basic composition into different size of capsule shells) capsule shells).
Copyright USP. All rights reserved.
Bracketing
` Bracketing can be applied to different container sizes of or different fills in the same container closure
tsystem...
` The use of a bracketing design would NOT be appropriate if it can not be demonstrated that theappropriate if it can not be demonstrated that the strengths or container sizes and fills selected for testing are indeed the extremes.
Copyright USP. All rights reserved.
Bracketing and Matrixing
o Example of simple bracketing design
Strengths 10mg 20mg 30mg
Batch 1 2 3 1 2 3 1 2 3
100s T T T - - - T T T100 s T T T T T T
Fill size 500s - - - - - - - - -
1000s
T T T - - - T T T
Copyright USP. All rights reserved.
Rationale for Matrixing
Long term trends are approximately linear Can design so that the effect of each factor may beCan design so that the effect of each factor may be
determined Can evaluate comparative stability of each
presentation Each storage condition has its own matrix Each testing can have its own matrix Each testing can have its own matrix Can revert to full testing Resource savingResource saving
22
What is Matrixing?
` The statistical design of a stability schedule such that a selected subset of the total number ofthat a selected subset of the total number of
possible samples are tested for all factor
combinations is tested at a specified time point. At
a subsequent time point, another subset of sample
for all factor combinations is tested. The design
assumes that the stability of each subset of
samples tested represent the stability of all samples
at a given time point
Copyright USP. All rights reserved.
at a given time point.
What is Matrixing?
` The differences in the samples for the same drug product should be identified as for example coveringproduct should be identified as, for example, covering
different batches, different strengths, different sizes of
the same container and closure, and in some cases,
different container/closure systems.
Copyright USP. All rights reserved.
Matrixing
o Example of one half factorial designTime point Months on stabilityTime point Months on stability
Batch 0 3 6 9 12 18 24 36
10 mg 1 T T - T T - T T10 mg 2 T T T T T T10 mg 2 T T - T T T - T10 mg 3 T - T - T T - T20 mg 1 T - T - T - T T20 mg 1 T - T - T - T T20 mg 2 T T - T T T - T20mg 3 T - T - T - T T
25
20mg 3 T T T T T
Matrixing
o Example of two third factorial design (1/3 reduction)Time point Months on stability
Batch 0 3 6 9 12 18 24 36
10 mg 1 T T - T T - T T
10 mg 2 T T T - T T - T10 mg 2 T T T T T T10 mg 3 T - T T T T T T20 mg 1 T - T T T T T Tg20 mg 2 T T - T T - T T20mg 3 T T T - T T - T
Copyright USP. All rights reserved.
g
Bracketing and Matrixing
Example of a complete complex designStrengths 10mg 20mg 30mg
Container size
X Y Z X Y Z X Y Z
Batch A T1 T2 T3 T2 T3 T1 T3 T1 T2
Batch B T2 T3 T1 T3 T1 T2 T1 T2 T3
Batch C T3 T1 T2 T1 T2 T3 T2 T3 T1
Time point
Months on stability
0 3 6 9 12 18 24 36T1 T - T T T T T TT2 T T - T T - T T
27
T3 T T T - T T - T
Bracketing and Matrixing
o Example of an incomplete complex designStrengths 10mg 20mg 30mg
Container size
X Y Z X Y Z X Y Z
Batch A T1 T2 - T2 - T1 - T1 T2Batch A T1 T2 T2 T1 T1 T2
Batch B - T3 T1 T3 T1 - T1 - T3
Batch C T3 - T2 - T2 T3 T2 T3 -
Time point
Months on stabilityp
0 3 6 9 12 18 24 36T1 T - T T T T T T
2
28
T2 T T - T T - T TT3 T T T - T T - T
Limitations of Matrixing
` All presentations must be set-up on storage` Realistically only the Long-Term storage is matrixedy y g g` May not pick up as much on differences` Data evaluation can be more complex` Data evaluation can be more complex` Confidence intervals may be wider` Regulatory experience is limited` Regulatory experience is limited
Copyright USP. All rights reserved.
Bracketing and Matrixing
` of complete removal of some presentations from testing and then reduced testing of those that remain. This is a
j d ti d d j tifi timajor reduction and needs justification.
` Not very common. Definitely need to work with the Agency to do this, unless there is lots of supportive data.
` Reduction of batches of all presentations
` Matrix different tests to different extents
Copyright USP. All rights reserved.